(P-1505) Cellular and Humoral Immunogenicity of 1 or 2 injections of mRNA-1403, a Multivalent Norovirus mRNA Vaccine, in Healthy Adults

Tuesday, October 21, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Presenting Author(s)

Rekha R. Rapaka, MD, PhD (she/her/hers)

Clinical Director
Moderna Therapeutics
Cambridge, MA, United States

MW

Meklit Workneh, MD, MPH

Moderna, Inc
Cambridge, Massachusetts, United States
BB

Brooke A. Bollman, PhD

Moderna, Inc
Cambridge, Massachusetts, United States
AR

Alexander Rumyantsev, MD, PhD

Moderna, Inc
Cambridge, Massachusetts, United States
Till Schoofs, MD

Director, Clinical Development Infectious Disease
Moderna, Inc
Cambridge, MA, United States
JO

Jaap Oostendorp, PhD

Sr Director
Moderna, Inc
Cambridge, MA, United States
GF

Gabrielle Fortier, MPH

Moderna
Salt Lake City, Utah, United States
KM

Kevin Mancini, MS

Moderna, Inc
Cambridge, Massachusetts, United States
WY

Wenlin Yuan, MS, PhD

Moderna, Inc
Cambridge, Massachusetts, United States
LB

Lauren Bailey, PhD

Moderna, Inc
Cambridge, Massachusetts, United States
TB

Tin Bartholomew, MA

Moderna, Inc
Cambridge, Massachusetts, United States
SM

Shannon McGrath, MS

Director of Clinical Cytometry
Moderna, Inc.
Norwood, Massachusetts, United States
HC

Heather L. Cahill, BSc

Scientist
Moderna Tx
Norwood, Massachusetts, United States
AB

Agi Buchanan, MD, PhD

Moderna, Inc.
Cambridge, Massachusetts, United States
KC

Katherine B. Carlson, PhD, MPH (she/her/hers)

Sr. Director, ID Epidemiology
Moderna
Cambridge, Massachusetts, United States
SS

Stephen J. Schrantz, Jr., MD

Director, Clinical Development
Moderna
Evanston, Illinois, United States
DF

Doran Fink, MD, PhD

Moderna, Inc
Cambridge, Massachusetts, United States